Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.
Marsden T, McCartan N, Brown L, Rodriguez-Justo M, Syer T, Brembilla G, Van Hemelrijck M, Coolen T, Attard G, Punwani S, Moore CM, Ahmed HU, Emberton M; ReIMAGINE Study Group. Marsden T, et al. Among authors: van hemelrijck m. PLoS One. 2022 Feb 24;17(2):e0259672. doi: 10.1371/journal.pone.0259672. eCollection 2022. PLoS One. 2022. PMID: 35202397 Free PMC article.
Incidence of second malignancies for prostate cancer.
Van Hemelrijck M, Feller A, Garmo H, Valeri F, Korol D, Dehler S, Rohrmann S. Van Hemelrijck M, et al. PLoS One. 2014 Jul 21;9(7):e102596. doi: 10.1371/journal.pone.0102596. eCollection 2014. PLoS One. 2014. PMID: 25047238 Free PMC article.
Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies.
van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium; Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Valdagni R, Perry A, Hugosson J, Rubio-Briones J, Bjartell A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH, van der Kwast T, Obbink H, van der Linden W, Hulsen T, de Jonge C, Kattan M, Xinge J, Muir K, Lophatananon A, Fahey M, Steyerberg E, Nieboer D, Zhang L, Guo W, Benfante N, Cowan J, Patil D, Tolosa E, Kim TK, Mamedov A, LaPointe V, Crump T, Kimberly-Duffell J, Santaolalla A, Nieboer D, Olivier JT, Rancati T, Ahlgren H, Mascarós J, Löfgren A, Lehmann K, Lin CH, Hirama H, Lee KS, Jenster G, Auvinen A, Bjartell A, Haider M, van Bochove K, Carter B, Gledhill S, Buzza M, Bangma C, Roobol M, Bruinsma S, Helleman J. van der Kwast TH, et al. Among authors: van hemelrijck m, van der kwast t, van bochove k, van der linden w. Eur Urol Oncol. 2019 May;2(3):333-336. doi: 10.1016/j.euo.2018.08.017. Epub 2018 Sep 13. Eur Urol Oncol. 2019. PMID: 31200849
Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH, Nieboer D, Morgan TM, Carroll PR, Roobol MJ; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium. Drost FH, et al. Eur Urol. 2019 Nov;76(5):693-702. doi: 10.1016/j.eururo.2019.07.041. Epub 2019 Aug 24. Eur Urol. 2019. PMID: 31451332
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.
Kalapara AA, Verbeek JFM, Nieboer D, Fahey M, Gnanapragasam V, Van Hemelrijck M, Lee LS, Bangma CH, Steyerberg EW, Harkin T, Helleman J, Roobol MJ, Frydenberg M; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Kalapara AA, et al. Among authors: van hemelrijck m. Eur Urol Oncol. 2020 Feb;3(1):80-91. doi: 10.1016/j.euo.2019.08.014. Epub 2019 Sep 26. Eur Urol Oncol. 2020. PMID: 31564531
Simulation in Urological Training and Education (SIMULATE): Protocol and curriculum development of the first multicentre international randomized controlled trial assessing the transferability of simulation-based surgical training.
Aydin A, Ahmed K, Van Hemelrijck M, Ahmed HU, Khan MS, Dasgupta P; SIMULATE Trial Group. Aydin A, et al. Among authors: van hemelrijck m. BJU Int. 2020 Jul;126(1):202-211. doi: 10.1111/bju.15056. Epub 2020 May 22. BJU Int. 2020. PMID: 32189446
Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
Singh S, Sandhu P, Beckmann K, Santaolalla A, Dewan K, Clovis S, Rusere J, Zisengwe G, Challacombe B, Brown C, Cathcart P, Popert R, Dasgupta P, Van Hemelrijck M, Elhage O. Singh S, et al. Among authors: van hemelrijck m. BJU Int. 2021 Jul;128(1):72-78. doi: 10.1111/bju.15281. Epub 2020 Nov 15. BJU Int. 2021. PMID: 33098158
Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial.
Brady L, Hayes B, Sheill G, Baird AM, Guinan E, Stanfill B, Vlajnic T, Casey O, Murphy V, Greene J, Allott EH, Hussey J, Cahill F, Van Hemelrijck M, Peat N, Mucci L, Cunningham M, Grogan L, Lynch T, Manecksha RP, McCaffrey J, O'Donnell D, Sheils O, O'Leary J, Rudman S, McDermott R, Finn S. Brady L, et al. Among authors: van hemelrijck m. PLoS One. 2020 Dec 18;15(12):e0243928. doi: 10.1371/journal.pone.0243928. eCollection 2020. PLoS One. 2020. PMID: 33338056 Free PMC article. Clinical Trial.
400 results